RIGL
RIGEL PHARMACEUTICALS INC
Nasdaq: RIGL · South San Francisco, CA · Healthcare
$30.72+0.64 (+2.13%)Closed
Market Cap$562.5M
Cash$24.4Mmost recent
Runwayprofitable
P/E (TTM)1.6EPS $19.48
52-Wk Range$18.42 – $50.96
Avg Volume485.2K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$30.72+201.2%
Pipeline

Drug candidates sponsored by RIGEL PHARMACEUTICALS · ClinicalTrials.gov

16 drugs · 27 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Olutasidenib
AML (Acute Myeloid Leukemia)+3 more
Recruiting
2027-04-30
1
Phase 3Fostamatinib
Covid19+8 more
Completed
2022-11-17past
3
Phase 3Fostamatinib disodium
Immune Thrombocytopenic Purpura+2 more
Completed
2024-04past
6
Phase 2R788
Rheumatoid Arthritis
Completed
2007-10past
1
Phase 2Fostamatinib disodium (R935788)
Rheumatoid Arthritis+1 more
Completed
2009-11past
3
Phase 2Fostamatinib Disodium / R935788
Purpura, Thrombocytopenic, Idiopathic
Completed
2010-04past
1
Phase 2Placebo
Asthma
Completed
2013-07past
1
Phase 2R932333
Lupus Erythematosus, Discoid+1 more
Completed
2013-09past
1
Phase 2Fostamatinib Disodium tablet 100 mg
IGA Nephropathy
Withdrawn
2015-09past
1
Phase 2R348 Ophthalmic Solution, 0.2%
Keratoconjunctivitis Sicca+1 more
Completed
2016-07past
3
Phase 2Fostamatinib 150 mg
IGA Nephropathy
Completed
2018-03-23past
1
Phase 2Fostamatinib 150 mg bid
Warm Antibody Autoimmune Hemolytic Anemia
Completed
2019-12past
1
Phase 1R906289 Monosodium (R289 Na)
Low Risk Myelodysplastic Syndromes
Recruiting
2026-08
1
Phase 2Olutasidenib + TMZ
High Grade Glioma+18 more
Recruiting
2029-06
1
Phase 2R926112
Rhinitis, Allergic, Seasonal
Completed—1
N/AFostamatinib disodium 100 mg
Immune Thrombocytopenic Purpura
No Longer Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for RIGL. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.